Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baselga, J.
Right arrow Articles by Albanell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baselga, J.
Right arrow Articles by Albanell, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S35-S41, 2001
© 2001 European Society for Medical Oncology

Symposium Article

Mechanism of action of anti-HER2 monoclonal antibodies

J. Baselga and J. Albanell

Medical Oncology Service, Hospital General Universitari Vall d'Hebron Barcelona, Spain

Correspondence to J. Baselga, MD Department of Medical Oncology Hospital General Universitari Vall d'Hebron Psg.Valld'Hebron, 119–129 08035 Barcelona Spain E-mail: baselga{at}hg.vhebron.es

The search for new methods of treating cancer, combined with advances in our understanding of carcinogenesis, molecular biology and technology, has resulted in the development of novel biologic agents with proven clinical efficacy. One such agent is trastuzumab (Herceptin), a humanized monoclonal antibody that targets the human epidermal growth factor receptor-2 (HER2). HER2 is a member of a family of receptors that interact with each other and various ligands to stimulate various intracellular signal transduction pathways involved in cell growth control. HER2 is overexpressed in 20%–30% of women with breast cancer and is associated with aggressive tumor characteristics and poor prognosis. Trastuzumab is the first humanized monoclonal antibody to be approved for therapeutic use and the first oncogene-targeted treatment with proven survival benefit in women with HER2-positive meta-static breast cancer. However, its mechanism of action has not been fully characterized and appears to be complex. This paper reviews current knowledge of the mechanism of action of trastuzumab, including HER2 protein downregulation, prevention of HER2-containing heterodimer formation, initiation of Gl arrest and induction of p27, prevention of HER2 cleavage, inhibition of angiogenesis, and induction of immune mechanisms. The significance of these mechanisms for selection of concomitant chemotherapy is also considered.

HER2, mechanism of action, monoclonal antibodies, signal transduction, Herceptin, trastuzumab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
V. Roy and E. A. Perez
Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer
Oncologist, November 1, 2009; 14(11): 1061 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Reilly
Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy
J. Nucl. Med., July 1, 2009; 50(7): 1017 - 1019.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Belkhiri, A. A. Dar, D. F. Peng, M. H. Razvi, C. Rinehart, C. L. Arteaga, and W. El-Rifai
Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells
Clin. Cancer Res., July 15, 2008; 14(14): 4564 - 4571.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi, A. Kapanen, M. Tanner, G. Vereb, et al.
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mol. Cancer Ther., July 1, 2007; 6(7): 2065 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, and R. Lupu
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
Ann. Onc., August 1, 2005; 16(8): 1253 - 1267.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.